Isomorphic Labs raises $5 billion Series C led by Sequoia and Greenoaks
Demis Hassabis said the Alphabet drug-discovery company will use the round to push its first treatment programs toward clinical trials, six months after a $2.1bn Series B.
Isomorphic Labs has raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital. Demis Hassabis, founder and chief executive, said the money will speed foundational models of biology, a deeper reading of systemic disease, and the company's first therapeutic programs on the way to clinical trials.
The company placed the round six months after a $2.1bn Series B in May. Bloomberg also noted a $600M raise in March 2025. Investors alongside the co-leads include Thrive Capital, Andreessen Horowitz, Alphabet and its GV and CapitalG funds, Tamesek and the Sovereign AI fund. Isomorphic described further backing from existing investors as a continued significant investment.
Isomorphic was spun out of DeepMind in 2021 and is part of Alphabet. Its software base includes AlphaFold, the Nobel Prize-winning system that predicts protein structures. The company is researching treatments for cancer and immune disorders, and it is scaling IsoDDE, its proprietary drug-design engine, together with an AI-designed pipeline of therapeutic candidates.
Hassabis said the design engines are generating molecules with what he called unprecedented precision and speed. Max Jaderberg, president, said the models produce repeatable scientific advances every week that become stronger molecular profiles with a chance of being new medicines, and that mixed teams of machine-learning researchers and drug hunters are regularly solving biological problems that had stalled traditional research for decades.
Isomorphic said it will keep developing IsoDDE, move further into new biology with highly advanced AI models, and build a partner ecosystem around mechanistic disease biology. It said the capital will support AI work and clinical development infrastructure as candidates advance toward trials, with Hassabis framing the goal as tangible impact for patients.